Results 71 to 80 of about 10,088 (191)

Rifaximin Treatment of Collagenous Colitis: A Randomised, Double-Blind, Placebo-Controlled Trial

open access: yesInflammatory Intestinal Diseases
Introduction: Collagenous colitis (CC) is a disabling disease primarily affecting elderly women. Sparse, well-documented treatment modalities exist, except for budesonide. Long-term and repetitive treatment with budesonide is often necessary.
Sabine Becker   +2 more
doaj   +1 more source

Efficacy of rifaximin against covert hepatic encephalopathy and hyperammonemia in Japanese patients.

open access: yesPLoS ONE, 2022
Covert hepatic encephalopathy (CHE) impairs patient quality of life and occurs in approximately 30% of liver cirrhosis (LC) cases. Japanese clinical practice guidelines recommend rifaximin to treat overt HE (OHE).
Masato Nakai   +13 more
doaj   +1 more source

The impact on hospital resource utilisation of treatment of hepatic encephalopathy with rifaximin-α [PDF]

open access: yes, 2016
Background & Aims: Rifaximin-α reduces the risk of recurrence of overt hepatic encephalopathy. However, there remain concerns regarding the financial cost of the drug.
Dillon, John   +25 more
core   +1 more source

A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers' diarrhea

open access: yes, 2006
Rifaximin was compared with placebo and ciprofloxacin for treatment of travelers' diarrhea in a randomized, double-blind clinical trial. Adult travelers (N = 399) consulting travel clinics in Mexico, Guatemala, and India were randomized to receive ...
Rifaximin Study Group   +17 more
core   +1 more source

Rifaximin for the treatment of diarrhoea-predominant irritable bowel syndrome

open access: yes, 2015
Rifaximin is a non-absorbable, semisynthetic antibiotic that acts as an inhibitor of bacterial RNA synthesis, with a broad spectrum of antibacterial activity.
Landi, Rosario   +16 more
core   +1 more source

Long-term management of hepatic encephalopathy with lactulose and/or rifaximin: a review of the evidence [PDF]

open access: yes, 2019
A consolidated overview of evidence for the effectiveness and safety/tolerability of hepatic encephalopathy (HE) treatment over the long term is currently lacking.
Hudson M, Schuchmann M
core   +2 more sources

Rifaximin in the treatment of hepatic encephalopathy

open access: yes, 2011
Maddalena Diana Iadevaia, Anna Del Prete, Claudia Cesaro, Laura Gaeta, Claudio Zulli, Carmelina LoguercioDepartment of Internistica Clinica e Sperimentale, F Magrassi e A Lanzara, Hepatogastroenterology Unit, Second University of Naples, Naples ...
Gaeta L   +5 more
core  

Comparison of Rifaximin and Lactulose for the Treatment of Hepatic Encephalopathy: A Prospective Randomized Study [PDF]

open access: yes, 2017
Rifaximin has been reported to be effective for the treatment of hepatic encephalopathy (HE) in Europe. However, it is unknown whether Rifaximin is effective for the treatment of HE in Koreans, therefore we conducted a open-label prospective randomized ...
안상훈   +11 more
core   +1 more source

Acid‐Stable Nitrofuran Triple Therapy With Rabeprazole and Amoxicillin Targeting Helicobacter pylori Infection

open access: yesMedComm, Volume 7, Issue 10, October 2026.
Overview: Novel nitrofuran derivatives were developed and evaluated against Helicobacter pylori to overcome antibiotic resistance and inflammation. Methods and Findings: In vitro assays using H. pylori 60190 and PMSS1 strains demonstrated potent antibacterial activity, reduced bacterial adhesion, and inhibited cytokine release from gastric epithelial ...
Nagendran Tharmalingam   +7 more
wiley   +1 more source

-Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth

open access: yes, 2005
BACKGROUND: Few controlled studies assessing choice and duration of antibiotic therapy for small intestinal bacterial overgrowth are available. AIM: To assess efficacy, safety and tolerability of different doses of rifaximin, a broad spectrum non ...
Lauritano, Ernesto Cristiano   +9 more
core  

Home - About - Disclaimer - Privacy